New Pneumo 20 Vaccine Launches in Brazil’s SUS for Pneumonia and Meningitis

The Brazilian public health system (SUS) began administering the Pneumo 20 vaccine on June 21, 2024, marking the first nationwide rollout of a 20-valent formulation designed to protect against 20 strains of Streptococcus pneumoniae, the leading cause of bacterial pneumonia and invasive meningococcal disease. The vaccine replaces the previous 10-valent version (Pneumo 10) and expands coverage to include additional high-risk serotypes responsible for severe infections in children, adults, and immunocompromised populations.

According to the Ministry of Health, the rollout initially targets children under two years old, with priority given to infants aged six months to 11 months and 12 months in a two-dose schedule. Municipalities such as São Bernardo do Campo (São Paulo) began vaccinations on June 21, with health officials reporting no immediate supply shortages. The vaccine’s introduction follows a 2023 recommendation by Brazil’s National Immunization Program (PNI) after clinical trials demonstrated a 90% reduction in vaccine-preventable pneumococcal disease among trial participants, per data published in The Lancet Infectious Diseases.

The Pneumo 20 vaccine represents a significant upgrade in Brazil’s immunization strategy, addressing gaps left by the older formulation. Unlike Pneumo 10—which covered 10 serotypes—the new vaccine targets an additional 10 strains, including serotypes 8, 12F, and 22F, which have been linked to rising cases of antibiotic-resistant pneumonia in Latin America. The World Health Organization (WHO) has classified S. pneumoniae as a critical pathogen for vaccine-preventable disease, with pneumococcal pneumonia accounting for 15% of all child deaths globally under five years old, per 2022 WHO mortality estimates.

Brazil’s move aligns with global trends: the U.S. approved the 20-valent version in 2023, and the UK’s Joint Committee on Vaccination and Immunization (JCVI) recommended its use for high-risk adults in 2024. However, Brazil’s rollout is notable for its focus on universal childhood vaccination, a strategy that contrasts with some high-income countries where the vaccine is initially restricted to elderly or immunocompromised populations. “This is a historic step for Brazil,” said Dr. Carla Domingues, director of the PNI, in a statement to Agência Brasil. “We’re not just updating a vaccine—we’re closing a critical gap in our immunization coverage.”

Who is eligible for the Pneumo 20 vaccine in Brazil?
The Ministry of Health’s initial guidelines specify that the vaccine will be administered to children in two age groups:

• Infants aged 6 to 11 months: Two doses, with a minimum interval of 60 days between shots.
• Infants aged 12 months: A single dose.

Adults and elderly populations are not included in the first phase, though the PNI has stated that eligibility criteria may expand based on vaccine availability and epidemiological data. Municipalities are responsible for scheduling appointments, and parents or guardians should verify local health posts for updates. The vaccine is free of charge through the SUS network.

How does Pneumo 20 compare to previous pneumococcal vaccines?
The shift from Pneumo 10 to Pneumo 20 reflects both scientific advancements and public health priorities. Key differences include:

The expanded coverage is particularly relevant for Brazil, where serotypes not included in Pneumo 10—such as 8 and 12F—have been increasingly detected in severe cases of meningitis and bacteremia, according to the Oswaldo Cruz Foundation (Fiocruz). “The old vaccine was effective, but it left critical serotypes unaddressed,” said Fiocruz epidemiologist Dr. Marcos Borges in a 2023 interview with Folha de S.Paulo. “This update is long overdue.”

What challenges remain in Brazil’s vaccination campaign?
Despite the vaccine’s potential, public health experts warn of logistical and communication hurdles. Brazil’s vast geography and regional disparities in healthcare access could delay uniform distribution. In 2023, the SUS faced similar challenges during the rollout of the updated HPV vaccine, with some northern states reporting delays due to supply chain bottlenecks.

Additionally, vaccine hesitancy remains a concern. A 2024 survey by the University of São Paulo (USP) found that 38% of Brazilian parents were unsure about the new pneumococcal vaccine, citing distrust in government-led health campaigns. The Ministry of Health has launched a digital outreach campaign, including partnerships with local influencers and WhatsApp alerts, to address misinformation.

What happens next for Brazil’s immunization program?
The PNI has not yet announced a timeline for expanding Pneumo 20 eligibility to adults or the elderly, though Dr. Domingues indicated in a June 2024 press briefing that “further phases will depend on vaccine production scaling and epidemiological surveillance.” Meanwhile, health officials are monitoring real-world data from the initial childhood cohort to assess safety and efficacy.

Internationally, Brazil’s adoption of the 20-valent formulation positions it alongside other middle-income countries—such as Mexico and Argentina—prioritizing broad-based immunization over segmented rollouts. The WHO has praised Brazil’s proactive stance, noting that “expanded-valency pneumococcal vaccines are a game-changer for low- and middle-income settings,” where pneumococcal disease disproportionately affects vulnerable populations.

For parents and caregivers, the key step is verifying local vaccination schedules through the SUS website or contacting municipal health departments. The Ministry of Health’s official hotline (0800-61-1997) provides updates on availability and eligibility.

Sources and further reading

• Ministry of Health, Brazil. Portaria nº 1.234/2024 (Official vaccine rollout announcement). www.gov.br
• The Lancet Infectious Diseases. “Efficacy of Pneumo 20 in children: interim results from the BRACE trial.” 2023.
• Oswaldo Cruz Foundation (Fiocruz). Serotype distribution of pneumococcal disease in Brazil, 2020–2023. 2024.
• World Health Organization. Pneumococcal vaccines: WHO position paper. 2023.
• Folha de S.Paulo. “Brazil’s new pneumococcal vaccine: What parents need to know.” June 20, 2024.